At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Market Closed 02-06 16:00:00 EST
12.58
+0.17
+1.37%
盘后12.58
+0.000.00%
19:42 EST
High12.94Low12.20Vol950.51K
Open12.82D1 Closing12.41Amplitude5.96%
Mkt Cap984.95MTradable Cap724.19MTotal Shares78.29M
T/O11.95MT/O Rate1.65%Tradable Shares57.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR) and Phathom Pharmaceuticals (PHAT)
TIPRANKS  ·  01-22
Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR) and Phathom Pharmaceuticals (PHAT)
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility
Simply Wall St.  ·  01-11
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility
Phathom Pharmaceuticals Announces $130 Million Public Offering
TIPRANKS  ·  01-09
Phathom Pharmaceuticals Announces $130 Million Public Offering
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY)
TIPRANKS  ·  01-08
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY)
BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike
Reuters  ·  01-08
BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga  ·  01-08
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, General Motors, Ford
Reuters  ·  01-08
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, General Motors, Ford
Phathom Pharmaceuticals Shares Fall 13.7% Premarket After Co Announces $130 Mln Equity Raise
THOMSON REUTERS  ·  01-08
Phathom Pharmaceuticals Shares Fall 13.7% Premarket After Co Announces $130 Mln Equity Raise
Phathom Pharmaceuticals Inc - Shares Sold at $16.00 Each, Pre-Funded Warrants at $15.999
THOMSON REUTERS  ·  01-08
Phathom Pharmaceuticals Inc - Shares Sold at $16.00 Each, Pre-Funded Warrants at $15.999
Phathom Pharmaceuticals Inc - Announces Pricing of Public Offering of 6.87M Shares
THOMSON REUTERS  ·  01-08
Phathom Pharmaceuticals Inc - Announces Pricing of Public Offering of 6.87M Shares
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  01-08
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Stocks to Watch: Globus Medical, L3Harris, Phathom
Dow Jones  ·  01-08
Stocks to Watch: Globus Medical, L3Harris, Phathom
Phathom Shares Fall on Public Offering
Dow Jones  ·  01-08
Phathom Shares Fall on Public Offering
BRIEF-Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Reuters  ·  01-08
BRIEF-Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise
Reuters  ·  01-08
BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise
BRIEF-Phathom Pharmaceuticals Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing
Reuters  ·  01-08
BRIEF-Phathom Pharmaceuticals Files For Mixed Shelf Offering Size Not Disclosed- SEC Filing
Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million
MT Newswires Live  ·  01-08
Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million
Phathom Pharmaceuticals Expects Operating Profitability in Second Half of 2026
Reuters  ·  01-08
Phathom Pharmaceuticals Expects Operating Profitability in Second Half of 2026
Phathom Pharmaceuticals Inc - Expects Q4 Net Revenues of $57-$58 Mln
THOMSON REUTERS  ·  01-08
Phathom Pharmaceuticals Inc - Expects Q4 Net Revenues of $57-$58 Mln
Press Release: Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Dow Jones  ·  01-08
Press Release: Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--